MRVI

Biotech Stock Movements: Biotech stocks experienced significant fluctuations in after-hours trading, with several companies rebounding after losses during regular trading hours, driven by clinical data, FDA designations, and financing news.

Stoke Therapeutics Surge: Stoke Therapeutics saw its stock rise to $33.95 (+11.42%) after presenting positive data on zorevunersen for Dravet syndrome in collaboration with Biogen at a recent conference.

Alpha Tau Medical Gains: Alpha Tau Medical's shares surged by 25.26% to $5.30 after announcing the treatment of its first patient in a pilot study for recurrent glioblastoma multiforme using its Alpha DaRT technology.

FDA Designation for Senti Biosciences: Senti Biosciences' stock increased to $1.60 (+3.92%) following the FDA granting RMAT designation to its investigational CAR-NK cell therapy for acute myeloid leukemia and other hematologic malignancies.

Investor Alert: Bragar Eagel & Squire, P.C. is investigating potential claims against Maravai LifeSciences Holdings, Inc. (MRVI) for long-term stockholders who experienced losses between August 7, 2024, and February 24, 2025, following a class action complaint filed on March 3, 2025.

Company Issues: Maravai announced a delay in its fiscal 2024 earnings release due to an error in revenue recognition and identified a material weakness in its internal controls, leading to a significant drop in share price.

Allegations: The class action complaint alleges that Maravai's board made misleading statements and failed to disclose critical information regarding the company's financial reporting and goodwill, which misled investors about its business prospects.

Contact Information: Long-term stockholders with information or questions are encouraged to contact Bragar Eagel & Squire, P.C. directly via phone or email for further assistance regarding their legal rights.